GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (STU:6JU) » Definitions » Short-Term Debt

BioCardia (STU:6JU) Short-Term Debt : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is BioCardia Short-Term Debt?

BioCardia's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.


BioCardia Short-Term Debt Historical Data

The historical data trend for BioCardia's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia Short-Term Debt Chart

BioCardia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCardia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioCardia Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


BioCardia Short-Term Debt Related Terms

Thank you for viewing the detailed overview of BioCardia's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia (STU:6JU) Business Description

Traded in Other Exchanges
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.

BioCardia (STU:6JU) Headlines

No Headlines